Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | DBH | P09172 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31750006 | 0.81 | RXRA (0.41) | IDO1TAAR1 | |
| SCHEMBL3734 | 0.78 | TAAR1 (0.52) | IDO1TAAR1AGXT | |
| SCHEMBL5201 | 0.76 | IDO1 (0.48) | IDO1TAAR1AGXT | |
| SCHEMBL12466515 | 0.74 | IDO1 (0.41) | IDO1CA12CA1CA9TAAR1 | |
| SCHEMBL14270585 | 0.71 | IDO1 (0.48) | IDO1CA12CA1CA9TAAR1 | |
| SCHEMBL1300421 | 0.70 | HTT (0.42) | CYP17A1CYP11B1DAO | |
| SCHEMBL5487052 | 0.69 | IDO1 (0.46) | IDO1CA12CA1CA9TAAR1 | |
| SCHEMBL120092 | 0.69 | IDO1 (0.46) | IDO1CA12CA1CA9TAAR1 | |
| SCHEMBL5733912 | 0.69 | IDO1 (0.46) | IDO1CA12CA1CA9TAAR1 | |
| SCHEMBL16105495 | 0.67 | IDO1 (0.50) | IDO1CA12CA1CA9TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4041393-B1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AG (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-12594267-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12492189-B2 | Solid forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4172157-B1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| CN-114901280-B | MrgprX2 antagonists and uses thereof | 德米拉公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20240376077-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4458415-A2 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | Gilead Sciences, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-114867529-B | Novel heteroaryl triazole compounds as pesticides | 拜耳公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240316018-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| WO-2014110297-A1 | (HETERO) ARYLACETAMIDE DERIVATIVES AS ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2013164292-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-07 | — | — | WO | disclosed |
| US-20130289074-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| WO-2010045013-A1 | PHENYL SUBSTITUTED THIENO [2,3-D] PYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093763-A1 | PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-6593480-B2 | Obesity, hyperglycemia | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| WO-2002070507-A2 | GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES | ABBOTT LABORATORIES (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | KARO BIO AB (SE) | 2001-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | IDO1 267/4885CA12 4193/4885CA1 4401/4885 |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | NR3C1, GPR119, NR3C2 | IDO1 3967/4885CA12 4817/4885CA1 4656/4885 |
| US-20240316018-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | SAP18, SLC11A2, CD4 | IDO1 2494/4885CA12 1441/4885CA1 2784/4885 |
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | CHKA, SLC5A7, SLC44A1 | IDO1 547/4885CA12 3032/4885CA1 668/4885 |
| US-12594267-B2 | Capsid inhibitors for the treatment of HIV | CTDSP1, POLR2H, POLR2E | IDO1 2581/4885CA12 3348/4885CA1 2933/4885 |
| US-12492189-B2 | Solid forms of an HIV capsid inhibitor | ZC3HAV1, GTF3C3, ZC3HAV1L | IDO1 1113/4885CA12 3910/4885CA1 1544/4885 |
| US-20240376077-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | IDO1 3387/4885CA12 3010/4885CA1 4509/4885 |
| US-20130289074-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPR55, GPR52 | IDO1 605/4885CA12 2489/4885CA1 3179/4885 |
| US-20100093763-A1 | PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | IDO1 409/4885CA12 4877/4885CA1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.